Ocriplasmin

From Ganfyd

Jump to: navigation, search

Contents

Introduction

Ocriplasmin is recombinant microplasmin protease being developed for pharmacological posterior vitreous detachment by cleaving the extracellular matrix that adheres the vitreous to the internal limiting membrane of the retina. In any condition where the vitreous can be abnormally adherent to the macula, leading to blindness from vitreomacular traction or macular hole it might have a role and thus be an option in exudative age-related macular degeneration, vitreomacular adhesion including macular holes, and macular oedema secondary to uveitis. It may facilitate penetration of anti-VEGF drugs into the retina.

Clinical Use

Indications

Administration

IO

Clinical Issues

Contra-indications

Cautions and Interactions

Side effects

  • Retinal detachment seems rare.

Special advice

Pharmacology

Plasmin cleaves laminin and fibronectin and its use in inducing posterior vitreous detachment lead to ocriplasmin.

Personal tools